2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological Activity
HS-1371 is a potent and ATP-competitive RIP3 inhibitor with an IC50 of 20.8 nM[1].
In Vitro
HS-1371 directly binds to RIP3 in an ATP-competitive and time-independent manner. HS-1371 has an inhibitory effect on RIP3 kinase activity in various cell lines[1]. HS-1371 can block RIP3 S227 phosphorylation[1]. HS-1371 rescues cells from RIP3-dependent necroptotic cell death but not apoptotic cell death[1].
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
AC-003 is a novel, orally administered small-molecule inhibitor targeting receptor-interacting protein kinase 1 (RIPK1), demonstrating therapeutic potential for the treatment of idiopathic pulmonary fibrosis (IPF).
Adavivint is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.
WZ4002 is a mutant selective EGFR inhibitor with IC50s of 2, 8, 3 and 2 nM for EGFRL858R, EGFRL858R/T790M, EGFRE746_A750 and EGFRE746_A750/T790M, respectively.
GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.
